Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

First Year in Review: Top Ten Things to Know about Biosimilar Reimbursement in the U.S.

April 14, 2016, Covington Alert

It has now been a full year since the Food and Drug Administration (“FDA”) approved the first biosimilar product to proceed under the new abbreviated biological pathway. With recent spotlights on the cost of pharmaceutical drug products, the potential of biosimilars to offer patients additional and more affordable choices has been widely discussed. Most recently, the Department of Health and Human Services’ 2017 Budget in Brief noted that the first approval under the abbreviated pathway could be the “next step to increasing treatment options for patients.” As the U.S. landscape continues to evolve, below are the top ten things to know about the reimbursement developments in the last year.

Share this article: